GRO Biosciences Inc.

Vision

GRObio is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. Protein therapies have historically been unable to overcome significant obstacles impeding the treatment of diseases. GRObio’s platform removes these limitations, transforming protein therapies for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve health outcomes for patients.

Approach

GRObio is redefining protein therapeutics by removing the fundamental limitations of producing proteins with non-standard amino acids (NSAAs) – protein building blocks that expand beyond the typical 20 amino acids.

The proprietary GRO platform is comprised of the first production organisms with modified genomes that enable the efficient production of NSAA proteins. The Company’s uniquely scalable and stable production platform delivers protein therapeutics with chemistries and properties previously inaccessible to protein engineering.

GRObio is advancing its first two families of NSAA platform chemistries to build its product pipeline. DuraLogic™ chemistries focus on therapeutic stability and dosing schedule, while ProGly™ chemistries provide biologics that reeducate the immune system to treat autoimmune disease, or to eliminate immunogenic side effects of protein-based therapies.

GRO Biosciences Inc. is addressing

• Leap 04 / Prevent and cure cancer
• Leap 06 / Reverse autoimmune diseases and chronic inflammation